

# Human Recombinant IFN-beta (CHO-expressed)

## Interferon-beta

Catalog #100-1720	20 µg
Catalog #100-1721	100 µg
Catalog #100-1722	1000 µg

## Product Description

Interferon beta (IFN- $\beta$ ), also known as type I interferon, is produced by fibroblasts, and in smaller amounts by plasmacytoid dendritic cells. Macrophages and endothelial cells secrete IFN- $\beta$  in response to a viral infection (Reder & Feng). IFN- $\beta$  binds to a receptor complex composed of IFNAR1 and IFNAR2, and initiates signal transduction via the JAK/STAT pathway; this culminates in the transcription and activation of many genes that control dendritic cell activation, T cell survival, NK cell activation, chemokine expression, lymph node retention, and antiproliferative and antiviral effects (Dunn et al.). IFN- $\beta$  is a first-line treatment for multiple sclerosis. It suppresses Th17 cells by affecting expression of IL-4, IL-10, and IL-27. IFN- $\beta$  was also shown to expand regulatory T cells and limit T cell trafficking to the central nervous system (Inoue & Shinohara). Out of the two variants of IFN- $\beta$  (IFN- $\beta$ 1 and IFN- $\beta$ 3), this product is the IFN- $\beta$ 1 form.

## Product Information

<b>Alternative Names:</b>	B cell interferon, Fibroblast interferon, IFNB1, Leukocyte interferon, Type I interferon
<b>Accession Number:</b>	P01574
<b>Amino Acid Sequence:</b>	MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN
<b>Predicted Molecular Mass:</b>	20 kDa
<b>Species:</b>	Human
<b>Product Formulation:</b>	Lyophilized from sterile sodium acetate, pH 4.5, 5% Trehalose, 5% mannitol, 0.01% Tween®-80.
<b>Source:</b>	CHO
<b>Purity:</b>	≥ 92%


## Specifications

<b>Activity:</b>	The specific activity is $\geq 5 \times 10^7$ units/mg ( $EC_{50} \leq 0.02$ ng/mL), as determined by antiviral assays using WISH cells infected with vesicular stomatitis virus.
<b>Endotoxin Level:</b>	Measured by kinetic Limulus amoebocyte lysate (LAL) analysis and is $\leq 1$ EU/ $\mu$ g protein.

## Preparation and Storage

<b>Stability and Storage:</b>	Store at -20 to -80°C. Stable as supplied for 12 months from date of receipt.
<b>Preparation:</b>	Centrifuge vial before opening. Reconstitute the product in sterile water to at least 0.25 mg/mL by pipetting the solution down the sides of the vial. Do not vortex. As a general guide, do not store at 2 - 8°C for more than 1 month or at -80°C for more than 3 months. Avoid repeated freeze-thaw cycles.

## Data



**Figure 1. Biological Activity and Molecular Mass of Human Recombinant IFN-beta (CHO-expressed)**

(A) The biological activity of Human Recombinant IFN-beta (CHO-expressed) was tested in an antiviral assay using WISH cells infected with vesicular stomatitis virus. The EC<sub>50</sub> in the above example is  $\leq 20$  pg/mL. (B) Human Recombinant IFN-beta (CHO-expressed) was resolved with SDS-PAGE under reducing conditions. Human Recombinant G-CSF has a predicted molecular mass of 20 kDa.

## Related Products

For a complete list of cytokines or peptide pools, as well as related products available from STEMCELL Technologies, visit [www.stemcell.com/cytokines](http://www.stemcell.com/cytokines) or contact us at [techsupport@stemcell.com](mailto:techsupport@stemcell.com).

## References

- Dunn GP et al. (2006) Interferons, immunity and cancer immunoediting. *Nat Rev Immunol* 6(11): 836–48.
- Inoue M & Shinohara ML. (2013) The role of interferon- $\beta$  in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes. *Immunology* 139(1): 11–8.
- Reder AT & Feng X. (2013) Aberrant type I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology. *Front Immunol* 4: 281.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2024 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.